What the two studies found
Event ·
ADA announcement ·
What happened
The American Diabetes Association announced two retatrutide studies on 26 June 2023. Both were phase 2 trials, a mid-stage part of human testing that examines whether a treatment works and what side effects it causes. Encouraging results still need further testing.
In the obesity trial, adults without type 2 diabetes lost weight over 48 weeks compared with placebo. The comparison came from placebo: it contained no active drug. That comparison helps show which changes may be due to the drug.
What it means
This was a result for the people in that study, over that period. It doesn’t predict how much weight an individual would lose. And 48 weeks can’t answer every question about taking a medicine for years.
Retatrutide acts on three hormone signals involved in appetite, blood sugar and energy use. That gives researchers a reason to study it. Counting hormone targets, though, doesn’t tell you which medicine works best. That takes a direct comparison.
The diabetes trial had a different job
Event ·
ADA announcement ·
What happened
The separate diabetes trial studied adults with type 2 diabetes and found improvements in blood sugar and body weight. Its comparison groups received placebo or another medicine. Unlike the obesity trial, everyone enrolled had type 2 diabetes.
What it means
The results can’t be rolled into one prediction for everyone who might take retatrutide. Blood sugar and weight are different measures, too. A useful headline keeps the finding attached to the people studied, rather than borrowing the strongest number from each trial.
Side effects are part of the result
The obesity trial reported stomach and bowel side effects, including nausea, and increases in heart rate. Those findings belong beside the weight loss. A strong result on the scales doesn’t settle the safety question.
These are June 2023 phase 2 findings. They offer early evidence, rather than final answers about long-term benefits and harms. The study’s date helps you place it in the research timeline.
Retatrutide remains an unapproved investigational drug. FDA’s safety warning says federal law does not allow compounding with it. That is the position in the FDA record reviewed for this report in October 2026. Questions about approved alternatives belong with a licensed U.S. clinician who can prescribe.